Immunofluorescence Assay Market

Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) – Global Forecast to 2026

Report Code: BT 6044 Feb, 2021, by marketsandmarkets.com

[203 Pages Report] The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years. However, quality concerns over antibodies are the major challenge in this market.

Immunofluorescence Assay Market

To know about the assumptions considered for the study, Request for Free Sample Report

Covid -19 Impact On The Immunofluorescence Assay Market

COVID-19 has disrupted healthcare services in most countries worldwide; the worst affected are the US, Russia, Spain, Italy, the UK, India, Germany, and Iran.

Immunofluorescence assays are used extensively for the detection of viral antigens, including COVID-19. As a result, the pandemic has increased the demand for immunofluorescence assay products across the globe. These are fast and simple methods that allow researchers to visualize the effects and dynamics of viral infections. In the current global scenario, such methods represent a crucial tool in preventing and treating these pathogens.

Global Immunofluorescence assay Market Dynamics

Driver: Increasing prevalence of chronic disease

Over the last few decades, the prevalence of chronic diseases has increased significantly across the globe. According to the WHO, by 2020, chronic diseases are estimated to account for 73% of all deaths and 60% of the global burden of diseases. Diabetes, cancer, infectious diseases, neurological disorders, autoimmune diseases, cardiovascular diseases, lung disorders, severe pancreatitis, and renal failure are major chronic diseases worldwide. According to the American Institute for Cancer Research, an estimated 18.1 million cancer cases were reported worldwide in 2018; this is projected to increase to 29.5 million by 2040.

Restraints: High instrument costs

In immunofluorescence assays, imaging instruments are used to visualize and locate the fluorescently labeled antibodies in a sample. These imaging instruments are expensive as they are equipped with advanced features and functionalities.

Opportunity: High growth opportunities in emerging markets

Emerging markets such as Brazil, China, and India are expected to offer potential growth opportunities to market players in the coming years. This can primarily be attributed to the diversified healthcare markets in these countries, coupled with the high incidence of infectious and chronic disorders, increasing healthcare expenditure, and the increasing number of R&D initiatives by various organizations. For example, China and India have both registered a high prevalence rate of diabetes.

Challenge: Lack of skilled professionals

 The demand for pathology services has increased significantly for clinical applications due to the increasing prevalence of chronic diseases. Histopathology technologies account for the majority of the tests performed on cancer patients. However, there is a dearth of trained staff in these laboratories. Many histopathologists have reached retirement age, and only a small number of histopathologists are being trained. On the other hand, laboratories are under pressure to process an increasing number of specimens with limited staff.

The kits segment accounted for the highest growth rate in the Immunofluorescence assay market, by product, during the forecast period

The Immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables and accessories. The kits segment accounted for the highest growth rate in the Immunofluorescence assay market in 2020. The demand for complete solutions from a single provider, like closed-system reagents with calibrated measurements of the required quantity of reagents and controls, among CROs, academic institutes, and research institutes is growing, contributing to this segment's high growth rate.

Indirect immunofluorescence segment accounted for the highest CAGR

Based on type, the immunofluorescence assays market is segmented into indirect immunofluorescence and direct immunofluorescence. In 2020, indirect immunofluorescence accounted for accounted for the highest growth rate. The major factors driving the growth of this segment are its advantages such as sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence.

Cancer accounted for the largest share of the immunofluorescence assay market in 2020

Based on disease, the immunofluorescence assays market is segmented into cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and other diseases. The  cancer accounted for the largest share of the global immunofluorescence assays market. The large share of this segment can be attributed to the increasing prevalence of cancer globally and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer.

Pharmaceutical & biotechnology companies accounted for the largest share of the immunofluorescence assay market in 2020

Based on end user, the immunofluorescence assays market is segmented intopharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostics centers, and contract research organizations. The  pharmaceutical & biotechnology companies accounted for the largest share of  the global immunofluorescence assays market. The increasing use of this technology in the study of various diseases and drug discovery & development processes are driving the growth of this segment.

Immunofluorescence Assay Market   by Region

North America accounted for the largest share of the immunofluorescence assay market in 2020

The immunofluorescence assays market is divided into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global immunofluorescence assays market. The large share of the North American region is mainly attributed to the rising incidence of chronic & infectious diseases, increasing R&D spending, increasing research activities, favorable government funding opportunities, and the presence of major key players in the region

Key Market Players

Some of the major players operating in this market are Thermo Fisher Scientific (US), Merck KGaA (Germany) and Danaher Corporation (US). In 2019, Thermo Fisher Scientific held the leading position in the immunofluorescence assay market. The company also has a strong geographic footprint, serving over 400,000 customers through pharmaceutical and biotechnology companies, hospitals and clinical diagnostic laboratories, universities,research institutions, and government agencies.Merck KGaA held the second position in the immunofluorescence assay market in 2019.

Scope of the report

Report Metric

Details

Market Size Available for Years

2019–2026

Base Year Considered

2019

Forecast Period

2021–2026

Forecast Units

Value (USD Billion)

Segments Covered

By product, type, disease, end user, and region.

Geographies Covered

North America (US, Canada), Europe (Germany, France, UK, Spain, Italy, and RoE), APAC (China, India, Japan and the RoAPAC), Latin America, and Middle-East &Africa.

Companies Covered

Thermo Fisher Scientific, Inc. (US), Abcam plc (UK), Bio-Rad Laboratories, Inc. (US), PerkinElmer Inc. (US), Merck KGaA (Germany), Werfen Company (Spain), Cell Signaling Technology, Inc. (US), MEDIPAN GmbH (Germany), Sino Biological, Inc. (China), Danaher Corporation (US), Maravai LifeSciences (US), Enzo Biochem, Inc. (US), Becton, Dickinson and Company (US), Olympus Corporation (Japan), Nikon Corporation (Japan), Bruker Corporation (US), Agilent Technologies (US), Zyagen, Inc. (US), Cellabs (Australia), J. Mitra & Co. Pvt. Ltd. (India), Abnova Corporation (Taiwan), EpiGentek Group (US), Elabscience, Inc. (US), AESKU GROUP GmbH (Germany), and MaxVision Biosciences Inc. (Canada)

This research report categorizes the immunofluorescence assay market into the following segments and subsegments:

By Products

  • Antibodies
  • Reagents
  • Kits
  • Instruments
  • Consumables and Accessories

By Type

  • Indirect Immunofluorescence
  • Direct Immunofluorescence

By Disease

  • Cancer
  • Infectious Diseases
  • Cardiovascular Diseases
  • Autoimmune Diseases
  • Other Diseases

By End User

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Hospitals & Diagnostic Centers

Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific
    • China
    • Japan
    • India
    • RoAPAC
  • Latin America
  • Middle-East & Africa

Recent Developments:

  • In 2020, Merck KGaA invested EUR 18 million (USD 21.09 million) to build a new Life Sciences Laboratory in Buchs, Switzerland, to accelerate and support research and development, analytical production, and quality control.
  • In 2019, Thermo Fisher Scientific, Inc. launched the fully automated EVOS M7000 microscope.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 21)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           FIGURE 1 IMMUNOFLUORESCENCE ASSAYS MARKET
           1.3.2 YEARS CONSIDERED FOR THE STUDY
           1.3.3 CURRENCY
    1.4 STAKEHOLDERS
    1.5 LIMITATIONS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 25)
    2.1 RESEARCH DATA
           FIGURE 2 IMMUNOFLUORESCENCE ASSAYS MARKET: RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
           FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                    2.1.2.1 Key data from primary sources
    2.2 MARKET SIZE ESTIMATION
           2.2.1 BOTTOM-UP APPROACH
           FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
           2.2.2 TOP-DOWN APPROACH
           FIGURE 5 TOP-DOWN APPROACH
           2.2.3 GROWTH FORECAST
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 33)
           FIGURE 7 IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
           FIGURE 8 IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2018 VS. 2023 (USD MILLION)
           FIGURE 9 IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
           FIGURE 10 IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
           FIGURE 11 GEOGRAPHIC SNAPSHOT: IMMUNOFLUORESCENCE ASSAYS MARKET

4 PREMIUM INSIGHTS (Page No. - 37)
    4.1 IMMUNOFLUORESCENCE ASSAYS MARKET OVERVIEW
           FIGURE 12 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE & COUNTRY (2020)
           FIGURE 13 INDIRECT IMMUNOFLUORESCENCE SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020
    4.3 IMMUNOFLUORESCENCE ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 14 CHINA TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 40)
    5.1 INTRODUCTION
    5.2 KEY MARKET DYNAMICS
           FIGURE 15 IMMUNOFLUORESCENCE ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing prevalence of chronic diseases
           TABLE 1 INCIDENCE OF CANCER, 2018 VS. 2040
                    5.2.1.2 Rising R&D and healthcare spending
           FIGURE 16 PHARMACEUTICAL R&D EXPENDITURE, BY GEOGRAPHY, 2010–2016
           FIGURE 17 GLOBAL CURRENT HEALTH EXPENDITURE PER CAPITA, 2015–2018
                    5.2.1.3 Growing industry-academia collaboration
                    5.2.1.4 Increasing government funding for life science research
           TABLE 2 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2017-2020)
                    5.2.1.5 Growing awareness about early disease detection
           5.2.2 RESTRAINTS
                    5.2.2.1 High instrument costs
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High growth opportunities in emerging markets
           TABLE 3 DIABETES PREVALENCE IN EMERGING ECONOMIES, 2019 VS. 2030 VS. 2045
           5.2.4 CHALLENGES
                    5.2.4.1 Quality concerns over research antibodies
                    5.2.4.2 Lack of skilled professionals
           TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018
    5.3 COVID-19 IMPACT ON THE IMMUNOFLUORESCENCE ASSAYS MARKET
           TABLE 5 IMMUNOFLUORESCENCE ASSAY TESTS APPROVED FOR COVID-19 DIAGNOSTICS
    5.4 PRICING ANALYSIS
           TABLE 6 IMMUNOFLUORESCENCE ASSAY PRODUCTS, AVERAGE SELLING PRICES (IN USD)
    5.5 VALUE CHAIN ANALYSIS
           FIGURE 18 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
    5.6 SUPPLY CHAIN ANALYSIS
           FIGURE 19 DIRECT DISTRIBUTION—STRATEGY PREFERRED BY PROMINENT COMPANIES
    5.7 ECOSYSTEM ANALYSIS OF THE IMMUNOFLUORESCENCE ASSAYS MARKET
           FIGURE 20 ECOSYSTEM ANALYSIS OF THE IMMUNOFLUORESCENCE ASSAYS MARKET
    5.8 PESTLE ANALYSIS

6 IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT (Page No. - 53)
    6.1 INTRODUCTION
           TABLE 7 IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    6.2 REAGENTS
           TABLE 8 IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 9 IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
           6.2.1 STAINS & DYES
                    6.2.1.1 Stains and dyes accounted for the largest share of the reagents segment in 2020
           TABLE 10 IMMUNOFLUORESCENCE STAINS & DYES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
           6.2.2 MEDIA & SERA
                    6.2.2.1 Serum-free media eliminates the risk of contamination by viruses
           TABLE 11 IMMUNOFLUORESCENCE MEDIA & SERA MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
           6.2.3 FIXATIVES
                    6.2.3.1 Fixative agents are required for the preservation of morphology and the antigenicity of target molecules
           TABLE 12 IMMUNOFLUORESCENCE FIXATIVES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
           6.2.4 BUFFERS
                    6.2.4.1 Buffers are widely used in drug development applications
           TABLE 13 IMMUNOFLUORESCENCE BUFFERS MARKET, BY COUNTRY, 2019-2026(USD MILLION)
           6.2.5 PROBES
                    6.2.5.1 The use of probes in research is rising owing to its versatile and quantitative capabilities
           TABLE 14 IMMUNOFLUORESCENCE PROBES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
           6.2.6 SOLVENTS
                    6.2.6.1 Organic solvents are widely used in pharmaceutical processes and immunofluorescence assays
           TABLE 15 IMMUNOFLUORESCENCE SOLVENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
           6.2.7 OTHER REAGENTS
           TABLE 16 OTHER IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    6.3 INSTRUMENTS
           TABLE 17 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 18 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
           6.3.1 MICROSCOPES
                    6.3.1.1 Technological advancements in microscopy techniques propel segment growth
           TABLE 19 IMMUNOFLUORESCENCE MICROSCOPES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
           6.3.2 IMAGING ANALYSIS SYSTEMS
                    6.3.2.1 Imaging analysis systems are widely used in diagnostics and clinical research
           TABLE 20 IMMUNOFLUORESCENCE IMAGING ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    6.4 ANTIBODIES
           TABLE 21 IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026(USD MILLION)
           TABLE 22 IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
           6.4.1 PRIMARY ANTIBODIES
                    6.4.1.1 The increasing demand for accurate and reliable antibodies coupled with rising R&D expenditure drives segment growth
           TABLE 23 PRIMARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
           6.4.2 SECONDARY ANTIBODIES
                    6.4.2.1 The low cost of production and versatility have ensured stable growth in the market for secondary antibodies
           TABLE 24 SECONDARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    6.5 KITS
           6.5.1 THE DEMAND FOR COMPLETE SOLUTIONS AMONG END USERS DRIVES THE GROWTH OF THIS SEGMENT
           TABLE 25 IMMUNOFLUORESCENCE KITS MARKET, BY COUNTRY, 2019-2026(USD MILLION)
    6.6 CONSUMABLES & ACCESSORIES
           TABLE 26 IMMUNOFLUORESCENCE CONSUMABLES & ACCESSORIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

7 IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE (Page No. - 72)
    7.1 INTRODUCTION
           TABLE 27 GLOBAL IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 28 COMPARISON BETWEEN DIRECT AND INDIRECT IMMUNOFLUORESCENCE TECHNIQUES
    7.2 INDIRECT IMMUNOFLUORESCENCE
           7.2.1 INDIRECT IMMUNOFLUORESCENCE ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2020
           TABLE 29 GLOBAL INDIRECT IMMUNOFLUORESCENCE ASSAYS MARKET, BY REGION/COUNTRY, 2019–2026 (USD MILLION)
    7.3 DIRECT IMMUNOFLUORESCENCE
           7.3.1 THE HIGH COST ASSOCIATED WITH DIRECT IMMUNOFLUORESCENCE MAY LIMIT THE GROWTH OF THIS MARKET
           TABLE 30 GLOBAL DIRECT IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE (Page No. - 76)
    8.1 INTRODUCTION
           TABLE 31 IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
    8.2 CANCER
           8.2.1 CANCER ACCOUNTED FOR THE LARGEST SHARE OF THE DISEASE SEGMENT IN 2020
           TABLE 32 CANCER PREVALENCE, BY TYPE (2018)
           TABLE 33 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
           TABLE 34 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 INFECTIOUS DISEASES
           8.3.1 THE RISING PREVALENCE OF INFECTIOUS DISEASES TO INCREASE THE ADOPTION OF IMMUNOFLUORESCENCE ASSAY TECHNIQUES
           TABLE 35 IMMUNOFLUORESCENCE ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 CARDIOVASCULAR DISEASES
           8.4.1 THE HIGH INCIDENCE OF CVD TO INCREASE THE ADOPTION OF IMMUNOFLUORESCENCE IMAGING TECHNIQUES
           TABLE 36 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    8.5 AUTOIMMUNE DISEASES
           8.5.1 THE PREVALENCE OF AUTOIMMUNE DISEASES HAVE INCREASED WORLDWIDE, THUS SUPPORTING THE GROWTH OF THIS SEGMENT
           TABLE 37 PREVALENCE OF AIDS
           TABLE 38 IMMUNOFLUORESCENCE ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    8.6 OTHER DISEASES
           TABLE 39 IMMUNOFLUORESCENCE ASSAYS MARKET FOR OTHER DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)

9 IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER (Page No. - 84)
    9.1 INTRODUCTION
           TABLE 40 IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026(USD MILLION)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
           9.2.1 PHARMA & BIOTECH COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE END-USER SEGMENT IN 2020
           TABLE 41 IMMUNOFLUORESCENCE ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
    9.3 ACADEMIC & RESEARCH INSTITUTES
           9.3.1 GROWING GOVERNMENT INVESTMENTS FOR R&D TO PROPEL MARKET GROWTH
           TABLE 42 IMMUNOFLUORESCENCE ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
    9.4 HOSPITALS & DIAGNOSTIC CENTERS
           9.4.1 THE RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT THE GROWTH OF THIS SEGMENT
           TABLE 43 IMMUNOFLUORESCENCE ASSAYS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
    9.5 CONTRACT RESEARCH ORGANIZATIONS
           9.5.1 EMERGING MARKETS ARE EXPECTED TO PROVIDE ROBUST GROWTH OPPORTUNITIES FOR CROS
           TABLE 44 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY/REGION, 2019-2026(USD MILLION)

10 IMMUNOFLUORESCENCE ASSAY MARKET, BY REGION (Page No. - 90)
     10.1 INTRODUCTION
           TABLE 45 IMMUNOFLUORESCENCE ASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)
     10.2 NORTH AMERICA
           FIGURE 21 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, SNAPSHOT
           TABLE 46 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 47 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 48 NORTH AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 49 NORTH AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 50 NORTH AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 51 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 52 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 53 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.2.1 US
                        10.2.1.1 The US dominates the North American market in terms of market share
           TABLE 54 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2019 VS. FY 2020 (USD BILLION)
           TABLE 55 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 56 US: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 57 US: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 58 US: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 59 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 60 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 61 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Support from government organizations is driving the growth of the immunofluorescence assays market in Canada
           TABLE 62 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 63 CANADA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 64 CANADA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 65 CANADA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 66 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 67 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 68 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.3 EUROPE
           TABLE 69 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 70 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 71 EUROPE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 72 EUROPE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 73 EUROPE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 74 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 75 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 76 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Germany holds the largest share of the European market
           TABLE 77 RESEARCH GRANTS PROVIDED IN GERMANY, 2015–2019
           TABLE 78 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 79 GERMANY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 80 GERMANY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 81 GERMANY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 82 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 83 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 84 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Growing R&D investments drive the market in the UK
           TABLE 85 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 86 UK: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 87 UK: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 88 UK: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 89 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 90 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 91 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Rising research activity supports market growth in France
           TABLE 92 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 93 FRANCE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 94 FRANCE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 95 FRANCE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 96 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 97 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 98 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Rising life science R&D and favorable funding scenario are key drivers of the Italian market
           TABLE 99 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 100 ITALY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 101 ITALY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 102 ITALY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 103 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 104 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 105 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Rising prevalence of chronic disease to support the market growth
           TABLE 106 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 107 SPAIN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 108 SPAIN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 117
           TABLE 109 SPAIN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 110 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 111 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 112 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.6 REST OF EUROPE
           TABLE 113 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 114 ROE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 115 ROE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 116 ROE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 117 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 118 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 119 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.4 ASIA PACIFIC
           FIGURE 22 ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAYS MARKET SNAPSHOT
           TABLE 120 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
           TABLE 121 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
           TABLE 122 APAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 123 APAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 124 APAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 125 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 126 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
           TABLE 127 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
             10.4.1 JAPAN
                        10.4.1.1 Japan is the largest market for immunofluorescence assays in the APAC
           TABLE 128 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
           TABLE 129 JAPAN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 130 JAPAN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 131 JAPAN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 132 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 133 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
           TABLE 134 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 China is the fastest-growing market for immunofluorescence assays
           TABLE 135 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
           TABLE 136 CHINA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 137 CHINA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 138 CHINA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 139 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 140 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
           TABLE 141 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Increasing government spending on healthcare to support market growth
           TABLE 142 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
           TABLE 143 INDIA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 144 INDIA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 145 INDIA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 146 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 147 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
           TABLE 148 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC
           TABLE 149 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
           TABLE 150 ROAPAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 151 ROAPAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 152 ROAPAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 153 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 154 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
           TABLE 155 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
     10.5 LATIN AMERICA
             10.5.1 GROWING CONTRACT RESEARCH & MANUFACTURING ACTIVITIES TO SUPPORT MARKET GROWTH
           TABLE 156 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
           TABLE 157 LATIN AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 158 LATIN AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 159 LATIN AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 160 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 161 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
           TABLE 162 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 INADEQUATE RESEARCH INFRASTRUCTURE TO HAMPER THE MARKET GROWTH IN THE REGION
           TABLE 163 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
           TABLE 164 MEA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 165 MEA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 166 MEA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 167 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
           TABLE 168 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
           TABLE 169 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 144)
     11.1 OVERVIEW
           FIGURE 23 KEY DEVELOPMENTS IN THE IMMUNOFLUORESCENCE ASSAYS MARKET (2017 TO 2020)
     11.2 MARKET SHARE ANALYSIS
           FIGURE 24 IMMUNOFLUORESCENCE REAGENTS, KITS, ANTIBODIES, AND CONSUMABLE & ACCESSORIES MARKET SHARE, BY KEY PLAYER (2019)
           FIGURE 25 IMMUNOFLUORESCENCE INSTRUMENTS MARKET SHARE, BY KEY PLAYER (2019)
     11.3 COMPETITIVE SCENARIO
             11.3.1 MARKET EVALUATION FRAMEWORK, 2017-2020
             11.3.2 PRODUCT LAUNCHES & APPROVALS
           TABLE 170 PRODUCT LAUNCHES & APPROVALS
             11.3.3 AGREEMENTS & COLLABORATIONS
           TABLE 171 AGREEMENTS & COLLABORATIONS
             11.3.4 ACQUISITIONS
           TABLE 172 ACQUISITIONS
             11.3.5 EXPANSIONS
           TABLE 173 EXPANSIONS
             11.3.6 OTHER DEVELOPMENTS
           TABLE 174 OTHER DEVELOPMENTS
     11.4 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY
             11.4.1 VENDOR EXCLUSION CRITERIA
             11.4.2 STARS
             11.4.3 EMERGING LEADERS
             11.4.4 PERVASIVE PLAYERS
             11.4.5 PARTICIPANTS
           FIGURE 26 IMMUNOFLUORESCENCE ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING
     11.5 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES
             11.5.1 PROGRESSIVE COMPANIES
             11.5.2 STARTING BLOCKS
             11.5.3 RESPONSIVE COMPANIES
             11.5.4 DYNAMIC COMPANIES
           FIGURE 27 IMMUNOFLUORESCENCE ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES

12 COMPANY PROFILES (Page No. - 153)
(Business overview, Products offered, Recent developments & MnM View)* 
     12.1 THERMO FISHER SCIENTIFIC, INC.
           FIGURE 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
     12.2 ABCAM PLC
           FIGURE 29 ABCAM PLC: COMPANY SNAPSHOT (2020)
     12.3 BIO-RAD LABORATORIES, INC.
           FIGURE 30 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2019)
     12.4 PERKINELMER, INC.
           FIGURE 31 PERKINELMER: COMPANY SNAPSHOT (2019)
     12.5 MERCK KGAA
           FIGURE 32 MERCK KGAA: COMPANY SNAPSHOT (2019)
     12.6 WERFEN COMPANY
           FIGURE 33 WERFEN COMPANY: COMPANY SNAPSHOT (2019)
     12.7 CELL SIGNALING TECHNOLOGY, INC.
     12.8 MEDIPAN GMBH
     12.9 SINO BIOLOGICAL, INC.
     12.10 DANAHER CORPORATION
           FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
     12.11 MARAVAI LIFESCIENCES
           FIGURE 35 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2019)
     12.12 ENZO BIOCHEM, INC.
           FIGURE 36 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2019)
     12.13 BECTON, DICKINSON AND COMPANY (BD)
           FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
     12.14 OLYMPUS CORPORATION
           FIGURE 38 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2020)
     12.15 NIKON CORPORATION
           FIGURE 39 NIKON CORPORATION: COMPANY SNAPSHOT (2020)
     12.16 BRUKER CORPORATION
     12.17 AGILENT TECHNOLOGIES
     12.18 ZYAGEN, INC.
     12.19 CELLABS
     12.20 J. MITRA & CO. PVT. LTD.
     12.21 ABNOVA CORPORATION
     12.22 EPIGENTEK GROUP
     12.23 ELABSCIENCE, INC.
     12.24 AESKU.GROUP GMBH
     12.25 MAXVISION BIOSCIENCES, INC.
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies. 

13 APPENDIX (Page No. - 195)
     13.1 INDUSTRY INSIGHTS
     13.2 DISCUSSION GUIDE
     13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.4 AVAILABLE CUSTOMIZATIONS
     13.5 RELATED REPORTS
     13.6 AUTHOR DETAILS

The study involved four major activities in estimating the current size of the immunofluorescence assay market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

Extensive primary research was conducted after acquiring knowledge about the global market scenario through secondary research. Primary interviews were conducted from both the demand (hospitals and non-hospital ) and supply sides (immunofluorescence assay manufacturers and distributors).

The following is a breakdown of the primary respondents:

Immunofluorescence Assay Markett  Size, and Share

To know about the assumptions considered for the study,download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the immunofluorescence assay market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size-using the market size estimation processes-the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the immunofluorescence assay industry.

Report Objectives

  • To define, describe, and forecast the immunofluorescence assaymarket by product, type, disease, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall immunofluorescence assaymarket
  • To analyze the opportunities in the market for stakeholders and to provide details of
    the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely,
    North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  •  To track and analyze competitive developments such as product launches, partnerships, and expansions in the immunofluorescence assaymarket
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Product Analysis:

  • Product matrix, which gives a detailed comparison of the product portfolios of each company

Geographic Analysis:

  • Further breakdown of the immunofluorescence assays market into specific countries in the Rest of Europe, Rest of Asia Pacific, and the Rest of the World
COVID-19

Get in-depth analysis of the COVID-19 impact on the Immunofluorescence Assay Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Immunofluorescence Assay Market

Request For Special Pricing
Report Code
BT 6044
Published ON
Feb, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Immunofluorescence Assay Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home